Professor Andrew Biankin

  • Regius Chair of Surgery/Director of Translational Research Centre (Translational Research Centre)

telephone: 0141 330 5670
email: Andrew.Biankin@glasgow.ac.uk

Research interests

Andrew Biankin is a surgeon-scientist whose research goals are to improve outcomes for individuals with pancreatic cancer through the development of early detection and novel therapeutic strategies based on molecular phenotyping and the delineation and implementation of biomarkers that facilitate clinical decision-making. He contributes to the International Cancer Genome Consortium through extensively characterising the genomic, transcriptomic and epigenomic aberrations in pancreatic cancer, and is extending this knowledge to a personalized model of cancer care, where molecular characteristics guide treatment decisions.

Cancer Research UK Profile

Group Members

Marc Jones: Laboratory Manager.  Marc.Jones@glasgow.ac.uk

Eirini-Maria Lampraki: PhD student. e.lampraki.1@research.gla.ac.uk

Kim Moran-Jones: Staff Scientist. Kim.Moran-Jones@glasgow.ac.uk

Liz Musgrove: Senior Research Fellow; Synergy Manager, Cancer Research UK Glasgow Centre.  Liz.Musgrove@glasgow.ac.uk

Associates

Fraser Duthie

Mark Duxbury. Consultant Hepatobiliary & Pancreatic Surgeon. MDuxbury@NHS.net Translational cancer research. Investigating the biology and clinical relevance of SIDT-family proteins in human cancer.

Janet Graham. Consultant Medical Oncologist and NRS Research Fellow BWOSCC. janet.graham@ggc.scot.nhs.uk

Nigel Jamieson

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • University of Glasgow Human Cancer Models Initiative Pilot: Clinical Hub
    Cancer Research UK
    2016 - 2018
     
  • CR-UK Centre renewal
    Cancer Research UK
    2016 - 2017
     
  • Using preoperative pancreatic endoscopic ultrasound to enable precision medicine for the management of pancreatic cancer
    Pancreatic Cancer Research Fund
    2015 - 2016
     
  • Clinical Training Award Cycle 2
    Cancer Research UK
    2015 - 2018
     
  • Glasgow Molecular Pathology (GMP) Node
    Medical Research Council
    2015 - 2018
     
  • CR-UK Centre renewal
    Cancer Research UK
    2015 - 2016
     
  • Defining Platinum and PARP Responsive Molecular Phenotypes of Pancreatic Cancer.
    Wellcome Trust
    2015 - 2020
     
  • Italian pancreatic cancer genome initiative
    Centre for Applied Research on Cancer
    2015 - 2016
     
  • Italian pancreatic cancer genome initiative
    Centre for Applied Research on Cancer
    2015 - 2015
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2017
     
  • CR-UK Centre renewal
    Cancer Research UK
    2014 - 2017
     
  • CR-UK Centre renewal
    Cancer Research UK
    2014 - 2015
     
  • Genotype Guided Stratified Therapy for Pancreatic Cancer
    Cancer Research UK
    2014 - 2016
     

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008
Number of items: 40.

2016

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, (doi:10.1038/nature16965)

2015

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A., and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology Hematology, 96(3), pp. 483-497. (doi:10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Jamieson, N. B., Chang, D. K., and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B., Rulach, R., Grimmond, S.M., Chang, D.K., and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi:10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Carlino, M.S. et al. (2015) New RAS-mutant pancreatic adenocarcinoma with combined braf and mek inhibition for metastatic melanoma. Journal of Clinical Oncology, 33(11), e52-e56. (doi:10.1200/JCO.2013.51.5783) (PMID:24821886)

Humphris, J., Chang, D. K., and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi:10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. OncoTarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Biankin, A. V., Piantadosi, S., and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi:10.1038/nature15819) (PMID:26469047)

Chin, V., Nagrial, A., Chou, A., Biankin, A. V., Gill, A., Timpson, P., and Pajic, M. (2015) Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, e17. (doi:10.1017/erm.2015.17) (PMID:26507949)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Tactacan, C.M., Phua, Y.W., Liu, L., Zhang, L., Humphrey, E.S., Cowley, M., Pinese, M., Biankin, A.V., and Daly, R.J. (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer, 14, 139. (doi:10.1186/s12943-015-0412-3) (PMID:26215634) (PMCID:PMC4517651)

2014

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi:10.1002/cncr.28863)

Hudson, A. M., Yates, T., Li, Y., Trotter, E. W., Fawdar, S., Chapman, P., Lorigan, P., Biankin, A., Miller, C. J., and Brognard, J. (2014) Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research, 74(22), pp. 6390-6396. (doi:10.1158/0008-5472.CAN-14-1020) (PMID:25256751)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi:10.1002/ijc.28765)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Quek, K. et al. (2014) A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. BioTechniques, 57(1), pp. 31-38. (doi:10.2144/000114189)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi:10.3748/wjg.v20.i24.7849)

Al-Ejeh, F. et al. (2014) Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), pp. 3187-3197. (doi:10.1158/1078-0432.CCR-14-0048) (PMID:24838526)

Jamieson, N. B., Chang, D. K., Grimmond, S. M., and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820)

Weissmueller, S. et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell, 157(2), pp. 382-394. (doi:10.1016/j.cell.2014.01.066)

Chang, D. K., Grimmond, S. M., and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi:10.1016/j.gde.2013.12.001)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi:10.1038/bjc.2013.722)

Chang, D. K., Grimmond, S. M., Evans, T. R.J., and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi:10.1158/2159-8290.CD-14-0001)

2013

Cowley, M.J., Chang, D.K., Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M., and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi:10.1007/s00534-013-0610-6)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi:10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi:10.1186/gm482)

2012

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi:10.1038/nature11547)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi:10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi:10.1093/annonc/mdr561)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi:10.1073/pnas.1202490109)

2011

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi:10.1016/j.stem.2011.10.002)

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi:10.1371/journal.pone.0029075)

2009

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi:10.1200/JCO.2008.20.5104)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi:10.1053/j.gastro.2009.04.009)

2008

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi:10.1038/sj.bjc.6604177)

Leong, R.W.L., Nguyen, N.Q., Meredith, C.G., Al–Sohaily, S., Kukic, D., Delaney, P.M., Murr, E.R., Yong, J., Merrett, N.D., and Biankin, A.V. (2008) In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology, 135(6), pp. 1870-1876. (doi:10.1053/j.gastro.2008.08.054)

This list was generated on Mon Jun 27 16:24:00 2016 BST.
Jump to: Articles
Number of items: 40.

Articles

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, (doi:10.1038/nature16965)

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A., and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology Hematology, 96(3), pp. 483-497. (doi:10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Jamieson, N. B., Chang, D. K., and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B., Rulach, R., Grimmond, S.M., Chang, D.K., and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi:10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Carlino, M.S. et al. (2015) New RAS-mutant pancreatic adenocarcinoma with combined braf and mek inhibition for metastatic melanoma. Journal of Clinical Oncology, 33(11), e52-e56. (doi:10.1200/JCO.2013.51.5783) (PMID:24821886)

Humphris, J., Chang, D. K., and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi:10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. OncoTarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Biankin, A. V., Piantadosi, S., and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi:10.1038/nature15819) (PMID:26469047)

Chin, V., Nagrial, A., Chou, A., Biankin, A. V., Gill, A., Timpson, P., and Pajic, M. (2015) Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, e17. (doi:10.1017/erm.2015.17) (PMID:26507949)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Tactacan, C.M., Phua, Y.W., Liu, L., Zhang, L., Humphrey, E.S., Cowley, M., Pinese, M., Biankin, A.V., and Daly, R.J. (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer, 14, 139. (doi:10.1186/s12943-015-0412-3) (PMID:26215634) (PMCID:PMC4517651)

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi:10.1002/cncr.28863)

Hudson, A. M., Yates, T., Li, Y., Trotter, E. W., Fawdar, S., Chapman, P., Lorigan, P., Biankin, A., Miller, C. J., and Brognard, J. (2014) Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research, 74(22), pp. 6390-6396. (doi:10.1158/0008-5472.CAN-14-1020) (PMID:25256751)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi:10.1002/ijc.28765)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Quek, K. et al. (2014) A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. BioTechniques, 57(1), pp. 31-38. (doi:10.2144/000114189)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi:10.3748/wjg.v20.i24.7849)

Al-Ejeh, F. et al. (2014) Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), pp. 3187-3197. (doi:10.1158/1078-0432.CCR-14-0048) (PMID:24838526)

Jamieson, N. B., Chang, D. K., Grimmond, S. M., and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820)

Weissmueller, S. et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell, 157(2), pp. 382-394. (doi:10.1016/j.cell.2014.01.066)

Chang, D. K., Grimmond, S. M., and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi:10.1016/j.gde.2013.12.001)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi:10.1038/bjc.2013.722)

Chang, D. K., Grimmond, S. M., Evans, T. R.J., and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi:10.1158/2159-8290.CD-14-0001)

Cowley, M.J., Chang, D.K., Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M., and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi:10.1007/s00534-013-0610-6)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi:10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi:10.1186/gm482)

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi:10.1038/nature11547)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi:10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi:10.1093/annonc/mdr561)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi:10.1073/pnas.1202490109)

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi:10.1016/j.stem.2011.10.002)

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi:10.1371/journal.pone.0029075)

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi:10.1200/JCO.2008.20.5104)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi:10.1053/j.gastro.2009.04.009)

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi:10.1038/sj.bjc.6604177)

Leong, R.W.L., Nguyen, N.Q., Meredith, C.G., Al–Sohaily, S., Kukic, D., Delaney, P.M., Murr, E.R., Yong, J., Merrett, N.D., and Biankin, A.V. (2008) In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology, 135(6), pp. 1870-1876. (doi:10.1053/j.gastro.2008.08.054)

This list was generated on Mon Jun 27 16:24:00 2016 BST.